Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TUMOURPRINT

Financiado

Cerrado

High Throughput Bioprinting of Tumour Models for Drug Development and Oncology R...

High Throughput Bioprinting of Tumour Models for Drug Development and Oncology Research CELLINK will develop and commercialise TumourPrint - a high throughput platform for bioprinting of live tumour models for pharmaceutical drug development and large-scale cancer research. Bioprinting constitutes the most advanced m... ver más

31/01/2021

BICO GROUP

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

BICO GROUP AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-01-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

BICO GROUP

2.45M€ | Lider

EIFFAGE INFRAESTRUCTURAS

431.17K€ | Participante

FCC CONSTRUCCION

760.92K€ | Participante

GIVASA

321.53K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BBBhybrid Advanced in vitro physiological models Towards real scale... 150K€ Cerrado

PRE2020-093689 Bioactive materials for therapy and diagnosis 99K€ Cerrado

ANAPRINT Additive Printing for Cell based Analysis 71K€ Cerrado

Laser-Bioprint Laser Based Bioprinter 150K€ Cerrado

SAF2011-22771 MATERIALES BIOMIMETICOS PARA SISTEMAS TERAPEUTICOS AVANZADOS 149K€ Cerrado

PTA2023-023813-I Técnico de Biomodelado e Impresión 3D 52K€ Cerrado

Duración del proyecto: 27 meses Fecha Inicio: 2018-10-29
Fecha Fin: 2021-01-31

Líder del proyecto

BICO GROUP AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto CELLINK will develop and commercialise TumourPrint - a high throughput platform for bioprinting of live tumour models for pharmaceutical drug development and large-scale cancer research. Bioprinting constitutes the most advanced method for fabricating fidel tissue models, using live cells in combination with cell-instructive bioinks (specially formulated hydrogels that provide cells with an optimal environment for survival, growth and proper 3D development). The high throughput platform - completely new to the market - is designed according to user needs. It will revolutionise drug development processes through serial production of fidel cancer models in an automated, precise and reproducible way. The platform offers unparalleled printing capacity and is integrated with robotics and none-destructive analytical methods capable of scoring drug responses in printed constructs. Current oncology approaches principally rely on unsatisfactory 2D mono-cell cultures and animal models to predict outcomes in humans, resulting in exasperatingly high attrition rates of cancer drug candidates in clinical trials. The economic and ethically challenging implications of failed trials provide CELLINK with a unique value proposition to drive willingness-to-pay for their disruptive platform. TumourPrint will address today’s pharmaceutical challenges by producing tumour models capable of mimicking size, heterogeneity and vascularity of the human tumour microenvironment in a fidel way. CELLINK has a proven track-record of successfully developing and commercialising products according to user needs; they developed the world’s first universal bioink, have commercialized three generations of bioprinters and optimised 18 cell-specific bioinks. Since the company’s establishment in 2016, CELLINK has commercialised its technology in over 40 countries, grown its organisation ten-fold and secured collaborations with several global pharmaceutical giants.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores